News of the day

• Ambit grabs 50M in a Series D. Their Lead is AC-220 a ph1 selective Flt3 compound.  In WO/2007/109120?

 

aetiology and limited data in: WO/2005/048953

• Rigel tacks on 3M for the Japanese rights to R-763.

Array: Bag ‘o’ cash en route

40M up front:

…Array will grant Celgene an option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets…

Looks like unpartnerds include: KSP, P38, P38/tie2, Erbb1-2,  RAF, TLR’s, etc…

ARQ-197

Hard to spit in the sink at ‘30 million for the Asian rights‘ to a ph1 compound…

WO/2006/086484

XL518

>> update >>   An Exelixis Mek application WO/2007/044515 published 4/19/07

So did the IND and deal actually beat the patent application? Either that or I’m missing something, because I can’t find it.

“XL518 is the second Exelixis compound designed to inhibit the RAS/RAF/MEK/ERK pathway with high potency and specificity, and the first to specifically target MEK,”

They’ve got an interesting RAF application in the stable, but I was under the impression that was the one to house the XL281 series.

hat tip: Xcovery, but of course.

Wyeth gets Jak’d up!

via Jak3 but of course – in an underanounced deal with Pharmacopeia:

…Wyeth will pay Pharmacopeia $5 million initially, as much as $9 million of research funding over the next three years, and as much as $175 million for reaching certain goals with the JAK3 kinase inhibitor drug.

While it’s likely they have a few which haven’t published yet, WO/2006/108103 is the most recent PCOP Jak3 application.

They’ve been at this stuff for a while – I reckon since WO/2001/047921 and have a recent Tet Lett on a related series. Check 2HK5 for a clue on how they bind.

>> update 1/25/07 >> US20070021443 Jak3 Pharmacopeia patent application